Effects of cabozantinib (thyroid cancer): A Synthesis of Findings from 25 Studies

  1. Home
  2. Effects of cabozantinib (thyroid cancer)
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of cabozantinib (thyroid cancer): A Synthesis of Findings from 25 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of cabozantinib (thyroid cancer): A Synthesis of Findings from 25 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Cabozantinib is an oral, multi-targeted tyrosine kinase inhibitor used to treat thyroid cancer. 3 , 12 , 24 , 9 , 15 , 16 These studies demonstrate that cabozantinib is effective in treating advanced metastatic medullary thyroid cancer, particularly in patients with the RET M918T mutation. 12 Cabozantinib is believed to inhibit angiogenesis and suppress cancer cell growth by blocking receptor tyrosine kinases such as VEGFR2, MET, and RET. 12 Compared to other tyrosine kinase inhibitors used to treat thyroid cancer, cabozantinib has been reported to prolong progression-free survival (PFS) and inhibit tumor growth. 10 Additionally, cabozantinib shows promise in treating advanced, radioiodine-refractory differentiated thyroid cancer. 5 , 25 Cabozantinib should not be taken with food; patients should eat at least 2 hours before or 1 hour after administration. 17 The dosage of cabozantinib may need to be adjusted for patients with impaired liver or kidney function. 1 Side effects of cabozantinib include diarrhea, hand-foot syndrome, weight loss, decreased appetite, nausea, fatigue, dysgeusia, hair color changes, and hypertension. 12 , 4 , 24 Cabozantinib interacts with CYP3A4 and P-glycoprotein, so caution is advised when using it concurrently with other medications. 24 Animal studies have shown that cabozantinib causes birth defects and reduced fertility in both males and females, making it unsuitable for pregnant women or those trying to conceive. 24 Male partners should also practice contraception. 24

Benefits and Risks

Benefit Summary

Cabozantinib has the potential to be effective in treating advanced metastatic medullary thyroid cancer, especially in patients with the RET M918T mutation. 12 Cabozantinib also shows promise in treating advanced, radioiodine-refractory differentiated thyroid cancer. 5 , 25

Risk Summary

Side effects of cabozantinib include diarrhea, hand-foot syndrome, weight loss, decreased appetite, nausea, fatigue, dysgeusia, hair color changes, and hypertension. 12 , 4 , 24 Cabozantinib interacts with CYP3A4 and P-glycoprotein, so caution is advised when using it concurrently with other medications. 24 Animal studies have shown that cabozantinib causes birth defects and reduced fertility in both males and females, making it unsuitable for pregnant women or those trying to conceive. 24 Male partners should also practice contraception. 24

Comparison Between Studies

Commonalities

Multiple studies indicate that cabozantinib is effective in treating advanced metastatic medullary thyroid cancer. 12 , 24 , 9 , 15 These studies also agree that cabozantinib inhibits angiogenesis and suppresses cancer cell growth by blocking receptor tyrosine kinases such as VEGFR2, MET, and RET. 12 Additionally, cabozantinib has been reported to prolong progression-free survival (PFS) and inhibit tumor growth compared to other tyrosine kinase inhibitors used to treat thyroid cancer. 10

Differences

The effectiveness of cabozantinib is more pronounced in patients with the RET M918T mutation. 12 Cabozantinib also shows promise in treating advanced, radioiodine-refractory differentiated thyroid cancer. 5 , 25 Cabozantinib should not be taken with food; patients should eat at least 2 hours before or 1 hour after administration. 17 The dosage of cabozantinib may need to be adjusted for patients with impaired liver or kidney function. 1 Side effects of cabozantinib include diarrhea, hand-foot syndrome, weight loss, decreased appetite, nausea, fatigue, dysgeusia, hair color changes, and hypertension. 12 , 4 , 24 Cabozantinib interacts with CYP3A4 and P-glycoprotein, so caution is advised when using it concurrently with other medications. 24 Animal studies have shown that cabozantinib causes birth defects and reduced fertility in both males and females, making it unsuitable for pregnant women or those trying to conceive. 24 Male partners should also practice contraception. 24

Consistency and Inconsistencies in the Results

Multiple studies indicate that cabozantinib is effective in treating advanced metastatic medullary thyroid cancer. 12 , 24 , 9 , 15 However, there are conflicting findings regarding its effectiveness in treating advanced radioiodine-refractory differentiated thyroid cancer. 5 , 25 Cabozantinib should not be taken with food; patients should eat at least 2 hours before or 1 hour after administration. 17 The dosage of cabozantinib may need to be adjusted for patients with impaired liver or kidney function. 1 Side effects of cabozantinib include diarrhea, hand-foot syndrome, weight loss, decreased appetite, nausea, fatigue, dysgeusia, hair color changes, and hypertension. 12 , 4 , 24 Cabozantinib interacts with CYP3A4 and P-glycoprotein, so caution is advised when using it concurrently with other medications. 24 Animal studies have shown that cabozantinib causes birth defects and reduced fertility in both males and females, making it unsuitable for pregnant women or those trying to conceive. 24 Male partners should also practice contraception. 24

Real-World Application Notes

Cabozantinib has the potential to be effective in treating advanced metastatic medullary thyroid cancer, especially in patients with the RET M918T mutation. 12 Cabozantinib also shows promise in treating advanced, radioiodine-refractory differentiated thyroid cancer. 5 , 25 Cabozantinib should not be taken with food; patients should eat at least 2 hours before or 1 hour after administration. 17 The dosage of cabozantinib may need to be adjusted for patients with impaired liver or kidney function. 1 Side effects of cabozantinib include diarrhea, hand-foot syndrome, weight loss, decreased appetite, nausea, fatigue, dysgeusia, hair color changes, and hypertension. 12 , 4 , 24 Cabozantinib interacts with CYP3A4 and P-glycoprotein, so caution is advised when using it concurrently with other medications. 24 Cabozantinib should not be used by pregnant women or those trying to conceive. Male partners should also practice contraception. 24

Limitations of Current Research

Cabozantinib's effectiveness requires further investigation. 24 , 5 Cabozantinib also shows promise in treating advanced, radioiodine-refractory differentiated thyroid cancer. 5 , 25 Cabozantinib should not be taken with food; patients should eat at least 2 hours before or 1 hour after administration. 17 The dosage of cabozantinib may need to be adjusted for patients with impaired liver or kidney function. 1 Side effects of cabozantinib include diarrhea, hand-foot syndrome, weight loss, decreased appetite, nausea, fatigue, dysgeusia, hair color changes, and hypertension. 12 , 4 , 24 Cabozantinib interacts with CYP3A4 and P-glycoprotein, so caution is advised when using it concurrently with other medications. 24 Cabozantinib should not be used by pregnant women or those trying to conceive. Male partners should also practice contraception. 24

Future Research Directions

Cabozantinib's effectiveness requires further investigation. 24 , 5 Cabozantinib also shows promise in treating advanced, radioiodine-refractory differentiated thyroid cancer. 5 , 25 Cabozantinib should not be taken with food; patients should eat at least 2 hours before or 1 hour after administration. 17 The dosage of cabozantinib may need to be adjusted for patients with impaired liver or kidney function. 1 Side effects of cabozantinib include diarrhea, hand-foot syndrome, weight loss, decreased appetite, nausea, fatigue, dysgeusia, hair color changes, and hypertension. 12 , 4 , 24 Cabozantinib interacts with CYP3A4 and P-glycoprotein, so caution is advised when using it concurrently with other medications. 24 Cabozantinib should not be used by pregnant women or those trying to conceive. Male partners should also practice contraception. 24

Conclusion

Cabozantinib has the potential to be effective in treating advanced metastatic medullary thyroid cancer, especially in patients with the RET M918T mutation. 12 Cabozantinib also shows promise in treating advanced, radioiodine-refractory differentiated thyroid cancer. 5 , 25 Cabozantinib should not be taken with food; patients should eat at least 2 hours before or 1 hour after administration. 17 The dosage of cabozantinib may need to be adjusted for patients with impaired liver or kidney function. 1 Side effects of cabozantinib include diarrhea, hand-foot syndrome, weight loss, decreased appetite, nausea, fatigue, dysgeusia, hair color changes, and hypertension. 12 , 4 , 24 Cabozantinib interacts with CYP3A4 and P-glycoprotein, so caution is advised when using it concurrently with other medications. 24 Cabozantinib should not be used by pregnant women or those trying to conceive. Male partners should also practice contraception. 24 If you are considering cabozantinib treatment, it's important to discuss the potential benefits and risks with your doctor to determine if it is the right option for you. 24

Literature analysis of 25 papers
Positive Content
22
Neutral Content
1
Negative Content
2
Article Type
1
1
1
13
25
1.

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib.

Author: NguyenLinh, HollandJaymes, RamiesDavid, MamelokRichard, BenrimohNatacha, CiricSabrina, MarburyThomas, PrestonRichard A, HeumanDouglas M, GavisEdith, LacySteven

Hepatic impairment
Renal impairment

Cabozantinib, a tyrosine kinase inhibitor, should be used with caution in patients with renal impairment and closely monitored in patients with hepatic impairment due to potential treatment-emergent toxicity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.

Author: DunnaNageswara Rao, KandulaVenkatesh, GirdharAmandeep, PuduthaAmareshwari, HussainTajamul, BandaruSrinivas, NayarisseriAnuraj

MTC treatment
Side effects

This study aims to identify high-affinity dual inhibitors targeting RET and VEGFR2, which could provide a more effective treatment option for medullary thyroid carcinoma (MTC) than single-target inhibitors. The study uses in silico methods to screen for compounds with optimal ADMET properties and pharmacophore features.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.

Author: ResteghiniC, CavalieriS, GalbiatiD, GranataR, AlfieriS, BergaminiC, BossiP, LicitraL, LocatiL D

Thyroid cancer treatment
Toxicity

Tyrosine kinase inhibitors (TKIs) are a type of cancer drug that can be very effective in treating thyroid cancer. However, TKIs can also cause serious side effects, so it's important for doctors and patients to be aware of these potential risks. This study discusses the importance of preventing TKI toxicity and how to manage side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

Molecular Targeted Therapies of Aggressive Thyroid Cancer.

Author: FerrariSilvia Martina, FallahiPoupak, PolittiUgo, MaterazziGabriele, BaldiniEnke, UlisseSalvatore, MiccoliPaolo, AntonelliAlessandro

Prolonged progression-free survival
Side effects

Tyrosine kinase inhibitors (TKIs) are emerging as new therapies for aggressive thyroid cancers, including differentiated thyroid carcinomas (DTCs) and medullary thyroid cancer (MTC). Vandetanib and cabozantinib are approved for MTC, while sorafenib and lenvatinib are approved for DTC refractory to radioiodine.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers.

Author: SubbiahVivek, YangDong, VelchetiVamsidhar, DrilonAlexander, Meric-BernstamFunda

Cancer therapy

This review discusses the role of RET gene alterations in various cancers and the development of targeted therapies. While multikinase inhibitors have shown limited efficacy, highly potent and selective RET inhibitors like pralsetinib and selpercatinib are demonstrating improved efficacy and a more favorable toxicity profile.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.

Author: DaduRamona, HuMimi N, GrubbsElizabeth G, GagelRobert F

metastatic MTC treatment

This chapter reviews the progress in the treatment of medullary thyroid carcinoma (MTC) using kinase inhibitors over the past 7 years. The development of these inhibitors has revolutionized the treatment of metastatic MTC and provided insight into the mechanisms by which RET causes C-cell transformation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.

Author: MacielLéa Maria Zanini, MagalhãesPatrícia Künzle Ribeiro

MTC treatment
Toxicity

This study discusses the current treatment options for medullary thyroid carcinoma (MTC), a rare type of thyroid cancer. The study highlights the importance of careful patient selection for tyrosine kinase inhibitor (TKI) therapy due to the high toxicity of these drugs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.

Author: ObaTakaaki, ChinoTatsunori, SomaAi, ShimizuTadafumi, OnoMayu, ItoTokiko, KanaiToshiharu, MaenoKazuma, ItoKen-Ichi

Thyroid cancer treatment
Adverse effects

This meta-analysis assessed the efficacy and toxicity of four tyrosine kinase inhibitors (TKIs) used for thyroid cancer treatment. The authors highlight the differences in their clinical efficacy and toxicity profiles, suggesting that each TKI may be more suitable for specific types of thyroid cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

11.

[Systemic therapies for advanced thyroid cancer - an update].

Author: BrandenburgTim, MachlahYara Maria, Führer-SakelDagmar

rrDTC treatment
Side effects

Multi-kinase inhibitors (MKIs) are approved for the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma (rrDTC) and medullary thyroid carcinoma (MTC) in Germany. This review summarizes recent developments in the treatment of advanced thyroid cancer, including the approval of Cabozantinib for rrDTC and Selpercatinib for MTC and rrDTC.

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : German

13.

Lenvatinib: Role in thyroid cancer and other solid tumors.

Author: CabanillasMaria E, HabraMouhammed Amir

Advanced thyroid cancer treatment
Hypertension
diarrhea
fatigue/asthenia
decreased appetite

This article discusses the use of lenvatinib, a small-molecule tyrosine kinase inhibitor, for the treatment of advanced thyroid cancer. It highlights the drug's mechanisms of action, clinical trial results, and adverse events.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

An Overview of Medullary Thyroid Cancer Cases Treated at Kuwait Cancer Control Center.

Author: SheteJitendra, AlSalehKhaled, SafwatReham, BedairAhmed, ElSherifyMustafa, HusseinAmany, NazeehMarwa, MohantyAsit

Improved survival
Treats MTC
Dose adjustments needed
Side effects

Medullary thyroid cancers (MTC) constitute about 5% of all thyroid cancers. Surgery is the cornerstone of the management, with total thyroidectomy and nodal dissection as main treatment. Adjuvant treatment with radiotherapy is case selective. The development of targeted therapy, specifically vandetanib and cabozantinib, has brought in a major advantage in managing metastatic MTC.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

15.

Cabozantinib in Thyroid Cancer.

Author: FallahiPoupak, FerrariSilvia M, Di BariFlavia, MaterazziGabriele, BenvengaSalvatore, MiccoliPaolo, AntonelliAlessandro

PFS improvement

Cabozantinib is a multitarget tyrosine kinase inhibitor. This study reviewed the anti-cancer effects of cabozantinib in preclinical and clinical models of various cancers. Cabozantinib improved progression-free survival in patients with medullary thyroid cancer and showed promising results in patients with differentiated thyroid cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers.

Author: WirthLori J, ShermanEric, RobinsonBruce, SolomonBenjamin, KangHyunseok, LorchJochen, WordenFrancis, BroseMarcia, PatelJyoti, LeboulleuxSophie, GodbertYann, BarlesiFabrice, MorrisJohn C, OwonikokoTaofeek K, TanDaniel S W, GautschiOliver, WeissJared, de la FouchardièreChristelle, BurkardMark E, LaskinJanessa, TaylorMatthew H, KroissMatthias, MedioniJacques, GoldmanJonathan W, BauerTodd M, LevyBenjamin, ZhuViola W, LakhaniNehal, MorenoVictor, EbataKevin, NguyenMichele, HeirichDana, ZhuEdward Y, HuangXin, YangLuxi, KheraniJennifer, RothenbergS Michael, DrilonAlexander, SubbiahVivek, ShahManisha H, CabanillasMaria E

Durable efficacy in medullary thyroid cancer
Low-grade toxic effects

Selpercatinib demonstrated durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer, with or without prior vandetanib or cabozantinib treatment.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.

Author: NguyenLinh, HollandJaymes, MamelokRichard, LabergeMarie-Kristine, GrenierJulie, SwearingenDennis, ArmasDanielle, LacySteven

medullary thyroid cancer treatment
drug interactions

The study evaluated the effects of food and esomeprazole on cabozantinib bioavailability in healthy subjects.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints.

Author: StumpSarah E, WhangYoung E, CronaDaniel J

Creatine kinase elevation
Musculoskeletal complaints

This case report describes a patient with renal cell carcinoma who developed creatine kinase (CK) elevation after starting cabozantinib treatment. CK elevation was associated with musculoskeletal complaints. Cabozantinib was discontinued, and CK levels returned to baseline. This suggests a potential for under-reported cabozantinib-induced CK elevations, and providers should monitor for musculoskeletal complaints during cabozantinib therapy.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

19.

Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.

Author: de CastronevesLuciana Audi, NegrãoMarcelo Vailati, de FreitasRicardo Miguel Costa, PapadiaCarla, LimaJosé Viana, FukushimaJulia T, SimãoEduardo Furquim, KulcsarMarco Aurélio Vamondes, TavaresMarcos Roberto, JorgeAlexander Augusto de Lima, de CastroGilberto, HoffPaulo Marcelo, HoffAna Oliveira

Improved MTC treatment
Sorafenib treatment

This study reports the authors' experience using sorafenib, a drug that blocks a specific pathway, to treat advanced medullary thyroid carcinoma (MTC).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

20.

Drug resistance profiles of mutations in the RET kinase domain.

Author: LiuXuan, ShenTao, MooersBlaine H M, HilbergFrank, WuJie

RET TKIs efficacy
RET kinase mutations

Mutations in the RET kinase domain may impact the sensitivity of RET TK inhibitors used to treat thyroid and lung cancer. Further research is needed to understand the influence of these mutations on drug efficacy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

21.

Discovery and optimization of selective RET inhibitors via scaffold hopping.

Author: LuoZhibo, WangLingli, FuZhifei, ShuaiBin, LuoMiaorong, HuGuoping, ChenJian, SunJikui, WangJiansong, LiJian, ChenShuhui, ZhangYang

Improved drug-like properties
Potent RET inhibition
Reduced off-target effects

This study focuses on the development of novel RET inhibitors for treating RET-rearranged cancers, such as thyroid and lung cancer. The researchers identified a promising compound, compound 9, which exhibits high potency and selectivity for RET while demonstrating fewer off-target effects compared to existing inhibitors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Current Guidelines for Management of Medullary Thyroid Carcinoma.

Author: KimMijin, KimBo Hyun

MTC diagnosis
MTC risk stratification
MTC treatment

This review summarizes the management of medullary thyroid carcinoma based on recent guidelines. It highlights advances in molecular diagnosis, risk stratification, and treatment options, including multi-kinase inhibitors and selective RET inhibitors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

23.

Tracheoesophageal fistula development following radiotherapy and tyrosine kinase inhibitors in a patient with advanced follicular thyroid carcinoma: a case-based review.

Author: S TemperleyTatiana, TemperleyHugo C, O'SullivanNiall J, CorrAlison, BrennanIan, KellyMichael E, PriorLisa

Patient counselling
TEF monitoring
Radiation necrosis
TEF development

A case of tracheoesophageal fistula (TEF) development in a patient with radioactive iodine-refractory metastatic follicular thyroid carcinoma (FTC) following treatment with tyrosine kinase inhibitors (TKI) and radiotherapy (RT) is reported. This highlights the importance of monitoring TEF development in this patient population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

24.

cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.

Author:

Bleeding
Diarrhea
Fistulae
Hand-foot syndrome
Hypertension
Thrombosis

This review discusses the use of cabozantinib for treating medullary thyroid cancer, a rare type of thyroid cancer. While cabozantinib is approved for this purpose, the study found that it does not improve survival and may have significant side effects.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

25.

Targeted Therapy in Thyroid Cancer: State of the Art.

Author: ValerioL, PieruzziL, GianiC, AgateL, BotticiV, LorussoL, CappagliV, PuleoL, MatroneA, ViolaD, RomeiC, CiampiR, MolinaroE, EliseiR

Thyroid cancer treatment
Drug side effects

Tyrosine kinase inhibitors (TKIs) represent a promising therapeutic option for advanced thyroid cancer, with sorafenib and lenvatinib for differentiated and poorly differentiated thyroid cancer, and vandetanib and cabozantinib for medullary thyroid cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.